COMMUNIQUÉS West-GlobeNewswire

Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy
02/02/2026
TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis [...]
EssilorLuxottica: Full-Year 2025 Results Conference Call Invitation
02/02/2026
Full-Year 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
IBA – Rachat d’Actions Propres
02/02/2026
Louvain-la-Neuve, Belgique, 2 février 2026 – 18h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules, annonce aujourd’hui le lancement d’un programme de rachat d’ [...]
H.H.C. Group Releases White Paper on Independent Reviews in an AI-Driven Claims Environment
02/02/2026
ROCKVILLE, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.) , the leader in reducing healthcare costs by providing high-quality cost containment through claim negotiation, repricing and independent review [...]
EssilorLuxottica: Full-Year 2025 Results Conference Call Invitation
02/02/2026
Full-Year 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
02/02/2026
Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 2 February 2026, 6 : 00 pm CET Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) ( [...]
KabaFusion and Nautic Partners Announce Completion of Significant Growth Investment
02/02/2026
LEXINGTON, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- KabaFusion (the “Company”), a nationally recognized leader in home and alternative site infusion, and Nautic Partners (“Nautic”) announced today that Nautic has [...]
IBA – Share buyback
02/02/2026
Louvain-la-Neuve, Belgium, February 2 nd , 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, [...]
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
02/02/2026
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss 1 . CagriSema achieved superior HbA 1c reduction of up to 1.91%- [...]
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
02/02/2026
Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapy Findings to inform ethical guidelines, future clinical trial protocols, and policy [...]
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
02/02/2026
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
02/02/2026
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
02/02/2026
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques HOUSTON, TX, Feb. 02, 2026 (GLOBE [...]
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
02/02/2026
GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership will improve [...]
CorMedix Therapeutics Announces Share Repurchase Program
02/02/2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
02/02/2026
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a [...]
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
02/02/2026
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the [...]
Cynet Appoints MacKenzie Brown as Vice President of Threat Intelligence Strategy
02/02/2026
Brown will be Cynet’s leading voice on adversary tactics to help partners understand and respond to threats faster BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cynet , the unified, AI-powered cybersecurity platform, has [...]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02/02/2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: [...]

Pages